Rationale: According to general view, aldehyde dehydrogenase-2 (ALDH2) catalyzes the high-affinity pathway of vascular nitroglycerin (GTN) bioactivation in smooth muscle mitochondria. Despite having wide implications to GTN pharmacology and raising many questions that are still unresolved, mitochondrial bioactivation of GTN in blood vessels is still lacking experimental support.
A ldehyde dehydrogenase-2 (ALDH2) has a wellestablished function in the detoxification of reactive aldehydes, in particular ethanol-derived acetaldehyde, in the liver. Because the liver enzyme is almost exclusively located in the mitochondrial matrix space, it is commonly designated as mitochondrial aldehyde dehydrogenase to differentiate it from the cytosolic isoform (ALDH1). 1 In 2002, Stamler et al 2 discovered that vascular ALDH2 catalyzes bioconversion of nitroglycerin to yield 1,2-glycerol dinitrate (GTN) and inorganic nitrite. This reaction appears to be associated with formation of a disulfide in the catalytic site, leading to mechanism-based enzyme inactivation in the absence of an appropriate reductant, like dithiothreitol, 2 dihydrolipoic acid, 3 or the thioredoxin/thioredoxin reductase system. 4 Based on the mitochondrial localization of liver ALDH2, it has been proposed that GTN bioactivation takes place in mitochondria of vascular smooth muscle cells. Reduction of GTN-derived nitrite to nitric oxide (NO) by components of the respiratory chain would then couple ALDH2-catalyzed GTN metabolism to activation of soluble guanylate cyclase (sGC) and vascular relaxation. 2 Mitochondrial GTN bioactivation, supported by the observation that isolated mitochondria generate NO bioactivity from added GTN, 5, 6 has been generally accepted in the field and has found its way into standard textbooks of pharmacology. 7 However, this view is questioned by several observations. Bioactivation of GTN by isolated mitochondria occurs with fairly low affinity and is not affected by agents that modulate respiratory rate. 5, 8 Inhibition of respiration by GTN requires high concentrations of the nitrate (100 -1000 mol/L) 9, 10 and is apparently unrelated to ALDH2 catalysis, 10 whereas exposure of blood vessels to therapeutically relevant low concentrations of GTN does not affect mitochondrial respiration. 11 Most importantly, ALDH2 was reported to be almost exclusively present in cytosolic fractions of rat and rabbit aortas. 12 Moreover, we found that purified ALDH2 catalyzes direct reduction of GTN to NO 13, 14 with submicromolar GTN affinity (Beretta, Frewein, Mayer, unpublished observations, 2011) , suggesting that direct reduction of GTN to NO by ALDH2 could explain sGC activation without invoking mitochondrial nitrite reduction. The present study was designed to clarify whether the subcellular localization of ALDH2 is relevant to vascular GTN bioactivity.
Methods
An expanded Materials and Methods section is available in the Online Data Supplement available at http://circres.ahajournals.org.
Animals
All animals received care in accordance with the Austrian law on experimentation with laboratory animals (last amendment, 2005), which is based on the U.S. National Institutes of Health guidelines. ALDH2 knockout (KO) mice were generated as described. 15 
Human Coronary Arteries
After approval by the local ethical committee, pieces of both right and left coronary arteries (main and peripheral vessels) were explanted from three nonfailing hearts not suitable for transplantation. Vessels were cleaned from the surrounding adipose tissue before Western blot analysis.
Adenovirus Preparation
The pAdEasy-1 vectors containing human ALDH2 cDNA in the absence (AdV-cALDH2) or presence of the murine ALDH2 mitochondrial signal sequence (AdV-mALDH2) under the human cytomegalovirus promoter and the control vector pAdEasy-1-CMV-LacZ were prepared using the AdEasy XL Adenoviral Vector System (Stratagene, La Jolla, CA) according to the manufacturer's instructions. Viruses were produced in HEK293 cells and purified on a CsCl gradient.
Aortic Ring Experiments
Aortas were removed, cut into halves, and incubated in Dulbecco's modified Eagle medium containing 10% fetal calf serum in the absence or presence of 2ϫ10 9 plaque-forming units (PFU) virus for 24 hours (AdV-cALDH2) or 30 hours (AdV-mALDH2) at 37°C in 95% air/5% CO 2 . After washing with phosphate-buffered saline, each half of the aortas was cut into two pieces and mounted in organ baths for isometric tension measurements as described. 16 
Localization of Overexpressed ALDH2 in Aortic Smooth Muscle Cells
Aortic smooth muscle cells were isolated from ALDH2 KO mice and immortalized as described. [17] [18] [19] Cells were infected with 2ϫ10 7 PFU AdV for 24 hours (AdV-cALDH2) or 30 hours (AdV-mALDH2), fixed, and permeabilized. 20, 21 Anti-ALDH2 antibody and the probe MitoTrackerRed (Invitrogen GmbH, Lofer, Austria) were used to localize ALDH2 and mitochondria, respectively. Microscopy was performed using a Leica SP2 confocal microscope (Leica Microsystems, Mannheim, Germany).
Generation of Aortic Smooth Muscle Cells Lacking Mitochondrial DNA (Rho0 Cells)
Immortalized ALDH2 KO aortic smooth muscle cells were incubated in Dulbecco's modified Eagle medium containing 5% fetal calf serum, 1 mmol/L pyruvate, 50 mg/L uridine, and 100 g/L ethidium bromide to generate Rho0 cells as described. 22 Characterization of the Rho0 cells is described in detail in the Online Data Supplement.
Expression and Purification of ALDH2 From Aortic Smooth Muscle Cells
ALDH2 KO aortic smooth muscle cells seeded on 20 175-cm 2 flasks were infected with 7ϫ10 8 PFU/flask AdV for 24 hours (AdVcALDH2) or 30 hours (AdV-mALDH2). After washing, cells were collected and sonicated. Cleared cell lysates were loaded on a p-hydroxyacetophenone-sepharose affinity column for purification of ALDH2 according to published protocols. 23, 24 ALDH2 dehydrogenase activity was measured as formation of NADH from NAD in the presence of 1.5 mmol/L formaldehyde by monitoring the increase in absorbance at 340 nm in a spectrophotometer. 25 
Determination of GTN Denitration
Aortas (two aortas per sample) or aortic smooth muscle cell lysates (200 g) were assayed for conversion of GTN (2 and 6 mol/L, respectively) into 1,2-glycerol dinitrate as described. 26 Untreated or Rho0 aortic smooth muscle cells were infected with 3ϫ10 8 PFU AdV and 6ϫ10 8 PFU AdV for 24 hours (AdV-cALDH2) or 30 hours (AdV-mALDH2).
Determination of GTN Bioactivation by Aortic Smooth Muscle Cell Lysates
Purified bovine lung sGC (50 ng) was incubated at 37°C with of 0.5 mmol/L [␣- 32 P]GTP and 100 mol/L GTN or 1 mol/L 2,2-diethyl-1-nitroso-oxyhydazine in the presence of 100 g of aortic smooth muscle cell lysates prepared from untreated and Rho0 aortic smooth muscle cells that had been infected with 3ϫ10 8 PFU AdV and 6ϫ10 8 PFU AdV for 24 hours (AdV-cALDH2) or 30 hours (AdV-mALDH2). The 32 P-cGMP was isolated and quantified by liquid scintillation counting as described. 27 
Western Blot Analysis
Cytosolic (10 -20 g of protein) and mitochondrial (20 -50 g of protein) fractions were subjected to immunoblotting as described in detail in the Online Data Supplement. Blots were probed with a rabbit polyclonal antibody to human ALDH2 or with a mouse monoclonal anti-␤ actin antibody. ALDH2 was quantified using purified human ALDH2 (25 ng) as standard assuming identical reactivity of the antibody for the murine protein.
Statistical Analysis
Individual concentration-response curves were fitted to a Hill-type model giving estimates of GTN potency (EC 50 ). One-way unpaired analysis of variance with post hoc Student-Newman-Keuls test was used for comparison between groups. PϽ0.05 was considered as statistically significant.
Results

Subcellular Localization of ALDH2
Subcellular localization of ALDH2 was studied in mouse liver, mouse aortas, and human coronary arteries. As shown in Figure 1A , approximately 85% of total ALDH2 expressed Figure 1B ). Blots with GAPDH and cytochrome c oxidase as cytosolic and mitochondrial markers, respectively, revealed a purity of Ͼ95% for both fractions ( Figure 2B ). The observation that ALDH2 was mainly present in the cytosol of murine aortas was further confirmed by blotting mitochondria-enriched particulate fractions (Online Figure I) . Similar results were obtained with rat aorta (approximately 95% cytosolic, data not shown). Figure  1C shows that human coronary arteries exhibit a similar profile in the subcellular distribution of ALDH2. More than 95% of the protein was found in cytosolic fractions prepared from main and peripheral segments of left and right coronary arteries, with an average of 15.9Ϯ0.6 and 0.64Ϯ0.20 ng/mg of tissue expressed in cytosol and mitochondria, respectively. Figure 2A shows the amount of ALDH2 in mitochondrial and cytosolic fractions of ALDH2 KO aortas subjected to AdV infection. ALDH2 was not detectable in cytosolic fractions after infection with AdV-mALDH2 or in mitochondrial fractions after infection with AdV-cALDH2, suggesting highly selective targeting of the protein. An overexposed blot is shown in Online Figure II . Infection with AdV-cALDH2 resulted in cytosolic ALDH2 expression levels (22.9Ϯ2.6 ng/mg tissue) identical to those of wild-type (WT) aortas ( Figures 1B, 2A) . Infection with AdV-mALDH2 resulted in significant overexpression of ALDH2 in mitochondria (18.6Ϯ2.8 ng/mg tissue). Thus, ALDH2 KO aortas contained comparable total amounts of ALDH2 after infection with both constructs, and mitochondrial expression levels were approximately six-fold higher than in WT after infection with AdV-mALDH2. The representative blot of the mitochondrial and cytosolic marker proteins, cytochrome c oxidase, and GAPDH, respectively, shown in Figure 2B demonstrates a purity of Ͼ95% for the subcellular fractions. Selective targeting of ALDH2 to cytosol and mitochondria was also evident in AdV-infected immortalized vascular smooth muscle cells that had been isolated from ALDH2 KO aortas. As shown in Figure 3 , the protein was present exclusively in mitochondria stained with MitoTrackerRed on infection of the cells with AdV-mALDH2 ( Figure 3A, B) . In contrast, expression of AdV-cALDH2 resulted in diffuse staining that is typical for cytosolic proteins. Note that mitochondria did not stain for ALDH2 in these cells ( Figure  3C, D) . As expected, ALDH2 KO cells did not show any ALDH2 staining at all ( Figure 3E ). 
Non-standard Abbreviations and Acronyms
ALDH2 Expression in AdV-Infected ALDH2 KO Aortas
Dehydrogenase Activity of ALDH2 Purified From Infected Aortic Smooth Muscle Cells
The dehydrogenase activity of ALDH2 was below the detection limit of currently available techniques in lysates of AdV-infected aortic smooth muscle cells as well as homogenates of isolated WT or AdV-infected aortas. Thus, we partially purified ALDH2 from aortic smooth muscle cells infected either with AdV-cALDH2 or with AdV-mALDH2 to test whether overexpression in mitochondria affected enzyme function. Infection with both viruses allowed the purification of approximately 0.30 mg of protein from 3ϫ10 8 cells. There was no significant difference in the rates of formaldehyde oxidation catalyzed by cytosolic or mitochondrial ALDH2 (142Ϯ4 and 134Ϯ5 nmol/min/mg, respectively), suggesting that both proteins were functionally intact.
GTN Biotransformation by Aortic Smooth Muscle Cells
GTN biotransformation by AdV-infected aortic smooth muscle cells was studied as GTN denitration (formation of 1,2-glycerol dinitrate) and activation of sGC by GTN-derived NO. To probe for a potential role of functional mitochondria, untreated cells were compared with Rho0 cells lacking mitochondrial DNA that were generated by treatment with ethidium bromide. As shown in Online Figure III , Rho0 cells exhibited virtually complete mitochondrial dysfunction and cytochrome c oxidase activity was decreased by Ͼ90%. As shown in Figure 4A , overexpression of cytosolic ALDH2 led to approximately four-fold increased rates of GTN denitration, whereas overexpression of the protein in smooth muscle mitochondria had no effect. The measured GTN reductase activities were even slightly higher in Rho0 cells, excluding a contribution of functional mitochondria to GTN biotransformation by AdV-cALDH2-infected cells. Similar results were obtained when GTN bioactivation was measured as activation of sGC added to aortic smooth muscle cell lysates. Again, infection with AdV-cALDH2 but not AdV-mALDH2 resulted in significant sGC activation, and the effect was more pronounced with Rho0 cell lysates.
GTN Reductase Activities of WT and AdV-Infected ALDH2 KO Aortas
The GTN reductase activity of ALDH2 was assayed as denitration of GTN by slices of WT and AdV-infected aortas. Controls (WT and KO) were incubated for 24 or 30 hours under identical conditions but without AdV to account for the effect of incubation time on ALDH2 activity (approximately 50% reduction after 24 or 30 hours of incubation). As shown in Figure 5 , WT aortas exhibited identical GTN reductase activities after incubation for 24 or 30 hours (0.38Ϯ0.05 pmol/min/mg each). In ALDH2 KO aortas, GTN denitration was close to the detection limit of the method (0.10Ϯ0.01 and 0.06Ϯ0.03 pmol/min/mg after 24 and 30 hours of incubation, respectively). Infection of ALDH2 KO aortas with AdVcALDH2 restored GTN denitration close to WT levels (0.32Ϯ0.06 pmol/min/mg). The low GTN reductase activity rendered it difficult to judge the effect of AdV-mALDH2 infection. The measured rates of denitration were two-fold higher than in controls (0.14Ϯ0.04 pmol/min/mg) but the difference was not significant (Pϭ0.116).
We observed no significant differences in the dehydrogenase activities of WT and ALDH2 KO aortas, and the ALDH2-specific inhibitor daidzin had no effect on aldehyde dehydrogenase activities of WT vessels (data not shown), suggesting that aldehyde oxidation is mainly catalyzed by other ALDH isoforms in murine aortas.
Aortic Relaxation
To test for GTN bioactivation, we measured relaxation of aortic rings in response to increasing concentrations of the nitrate. As shown in Figure 6A , GTN had a biphasic effect in WT rings with an EC 50 of 130Ϯ48 nmol/L calculated for the high-affinity phase (1 nmol/L-1 mol/L). Incubation of the vessels for 24 hours led to an approximately 10-fold loss of GTN potency as compared to freshly isolated mouse aorta, but the relaxant response to GTN of incubated WT aortas was still considerably higher as compared to KO vessels ( Figure  6B ). The loss of GTN potency was accompanied by a reduction of GTN reductase activity from 0.77Ϯ0.18 to 0.38Ϯ0.05 pmol 1,2-glycerol dinitrate/min/mg. There was no significant difference between rings incubated for 24 or 30 hours, indicating that ALDH2 activity was largely preserved in WT vessels even after 30 hours of incubation. The 30-hour controls were omitted in Figure 6 for reasons of clarity but are shown in Online Figure IV . ALDH2-deficient rings showed residual relaxation to GTN with an EC 50 of approximately 30 mol/L, but the high-affinity phase was completely absent. Overexpression of ALDH2 in mitochondria of KO aortas (AdV-mALDH2) to six-fold WT levels had no effect on the GTN response (EC 50 ϭ26Ϯ7.6 mol/L). In contrast, cytosolic overexpression of the protein (AdV-cALDH2) fully restored GTN-induced relaxation. Interestingly, the vessels containing ALDH2 exclusively in the cytosol exhibited a monophasic response to GTN that occurred with an EC 50 of 2.8Ϯ0.75 mol/L, corresponding to a 10-fold to 20-fold left-ward shift of the concentration-response curves obtained with ALDH2 KO or AdV-mALDH2 rings. Note that relaxation of AdV-cALDH2 vessels at high concentrations of GTN (Ͼ1 mol/L) was considerably enhanced as compared to WT.
Discussion
The subcellular distribution of ALDH2 in rodent and human blood vessels is in striking contrast to the predominant mitochondrial localization of the protein in liver and, according to a recent study, 30 murine cardiac tissue. As a nuclear-encoded protein, liver ALDH2 contains an N-terminal 19-amino-acid signal peptide for translocation into mitochondria 31 by transfer along a series of mitochondrial outer membrane proteins with increasing affinity for basic ligands. 32 The present data suggest that vascular ALDH2 is mainly expressed in its mature form lacking the signal peptide, presumably because of alternative splicing. Alternative splicing of the ALDH2 gene has been demonstrated in human tissues (see entry in the AceView database 33 ). This raises the possibility that differences in the subcellular localization of the protein may at least partially explain the effect of vessel size on the potency of GTN. 34 The therapeutic effect of GTN is attributable to dilation of coronary arteries and dilation of venous capacitance vessels, resulting in increased blood supply to the heart and reduced cardiac preload, respectively. Our data with human coronary arteries demonstrate cytosolic expression of ALDH2 in therapeutically relevant arterial vessels, but the subcellular localization of the enzyme in veins is unknown.
There is barely any conclusive experimental evidence supporting the generally assumed involvement of mitochondria in vascular GTN bioactivation. Sydow et al 35 showed that knockdown of mitochondrial DNA by ethidium bromide in cultured endothelial cells led to decreased cGMP accumulation in response to GTN. However, the usefulness of endothelial cells as a model for vascular GTN bioactivation is questionable. Because endothelium-denuded blood vessels are more sensitive to GTN than endothelium-containing vessels, 36,37 endothelial cells are probably not involved in the generation of NO bioactivity. In addition, it is unknown whether endothelial cells express significant amounts of cytosolic ALDH2 and even native cells containing functional mitochondria exhibit only poor cGMP response to GTN. 35 The same applies to a study on S-nitrosation of mitochondrial proteins by preconditioning with GTN in a model of endothelial ischemia-reperfusion injury. 38 In the present study, we found that Rho0 aortic smooth muscle cells exhibited increased rather than decreased response to GTN relative to the maximal effect of the NO donor 2,2-diethyl-1-nitroso-oxyhydazine. These data exclude a contribution of functional mitochondria to GTN bioactivation by overexpressed ALDH2 and agree well with the enhanced relaxation to Ͼ1 mol/L GTN of aortas infected with AdVcALDH2 as compared to WT vessels.
Together with our previous studies showing that purified ALDH2 catalyzes direct reduction of GTN to NO 13, 14 with submicromolar GTN affinity (Beretta, Frewein, Mayer, unpublished observations, 2011) , the present data point to a simple model of GTN action in blood vessels, according to which the nitrate is metabolized by ALDH2 in the cytosol of vascular smooth muscle, resulting in formation of NO and activation of (cytosolic) sGC. The complex GTN/ALDH2 reaction 39 may yield additional and as-yetunknown reactive species that trigger oxidative stress leading to adverse effects of nitrate therapy, including tolerance and endothelial dysfunction. 40 This seemingly straightforward model is questioned by the failure of at least three independent laboratories to detect GTNderived NO in blood vessels. 11, 41, 42 Formation of S-nitrosoglutathione rather than NO has been proposed as possible explanation, 6 but activation of sGC by S-nitrosoglutathione requires release of NO, 43, 44 leaving the problem unresolved. Although the negative findings might reflect a true lack of NO formation, it is conceivable that cytosolic ALDH2 interacts in a locally constrained manner with sGC, resulting in significant cGMP accumulation by low concentrations of free NO that are below the detection limit of C-labeled GTN as described in Methods, followed by quantification of reaction products by radio thin layer chromatography. B, 100 g of cell lysates were incubated at 37°C for 10 minutes in the presence of 50 ng sGC, followed by isolation and quantification of cGMP as described in Methods. Data are expressed relative to maximal cGMP formation caused by 1 mol/L 2,2-diethyl-1-nitroso-oxyhydazine. * PϽ0.05 vs untreated; #PϽ0.001 vs untreated; §PϽ0.0001 vs untreated; †PϽ0.05 vs control; ‡PϽ0.0005 vs control. All data are mean valuesϮstandard error (SE) of four independent experiments. the analytic techniques currently available. Future work is necessary to clarify this issue.
As reported previously, 6 GTN caused biphasic relaxation of WT aortic rings with a high-affinity phase that was absent in ALDH2-deficient and AdV-mALDH2 aortas but restored on cytosolic overexpression of ALDH2. In contrast to WT, rings expressing ALDH2 exclusively in the cytosol exhibited a monophasic response to GTN with an EC 50 of 2.8 mol/L. Comparison of the GTN concentration-response of WT and AdV-cALDH2 rings indicates that relaxation of WT vessels is antagonized at GTN concentrations Ն1 mol/L by a mechanism that is absent in vessels containing only cytosolic ALDH2. A possible explanation would be NO scavenging by superoxide generated in the course of GTN metabolism by mitochondrial ALDH2. 35 The view that functional mitochondria counteract cytosolic GTN bioactivation is also supported by our data showing that disrupting mitochondrial function with ethidium bromide (generation of Rho0 cells) led to significantly increased cGMP accumulation in response to GTN ( Figure 4B ). Considering the potential role of mitochondrial superoxide formation in the development of nitrate tolerance, our proposal of mitochondrial GTN metabolism compromising GTN bioactivity agrees well with the observation that mice lacking mitochondrial superoxide dismutase are nitrate-tolerant. 45 The low rates of GTN denitration catalyzed by AdV-mALDH2 rings may reflect limited access of GTN to the mitochondrial matrix, although we cannot exclude that the protein overexpressed in mitochondria was dysfunctional.
In summary, our data suggest that the therapeutically relevant high-affinity component of vascular GTN bioactivation is mediated by cytosolic ALDH2. GTN metabolism catalyzed by the enzyme expressed in mitochondria appears to counteract relaxation through an unknown mechanism that becomes significant only at high GTN concentrations and may involve an oxidative stress response of mitochondria.
Limitations of the Study
Although 85% to 95% of rodent and human vascular ALDH2 is cytosolic, it is conceivable that a "micropopulation" of functionally active ALDH2 expressed in mitochondria is responsible for GTN bioactivation in vivo but becomes dysfunctional or mislocalized on overexpression with the AdV system. We cannot exclude this possibility with certainty because of our failure to detect significant rates of GTN denitration by blood vessels overexpressing ALDH2 in mitochondria. Partial purification of the enzyme from AdVinfected aortic smooth muscle cells showed that the cytosolic and mitochondrial proteins exhibited virtually identical dehydrogenase activities, suggesting that overexpression in mitochondria did not significantly impair enzyme function. However, activity of purified ALDH2 does not necessarily reflect activity of the enzyme in situ and dehydrogenase activity is not a surrogate for GTN reductase activity.
The loss in vascular reactivity that occurred during the unavoidable long-term incubation of the blood vessels may be considered as another potential problem, although the response to GTN of incubated WT aortas was still considerably higher as compared to ALDH2-deficient vessels ( Figure 6B ). 
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